← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tengen Biomedical Co.
Rockville, MD
$4,825,820
Total funding
4
Grants
Funding over time
peak $1.3M · FY2006–23$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,825,820 · 4
By mechanism
R42$3,000,000 · 1
R41$1,249,060 · 2
R43$576,760 · 1
Investigators at Tengen Biomedical Co.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2023 · AI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2021 · AI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2022 · AI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$300,000
R41 · FY2018 · AI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$300,000
R41 · FY2017 · AI
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate$298,530
R41 · FY2022 · AI
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate$298,530
R41 · FY2023 · AI
Development of Pseudoinfectious VLP as Novel JEV Vaccine$292,296
R43 · FY2006 · AI
Development of Pseudoinfectious VLP as Novel JEV Vaccine$284,464
R43 · FY2007 · AI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$52,000
R41 · FY2021 · AI